Evidence map›Paper›PMID 36266946›Full record

ArticleCancer medicine2023

Prevalence, characteristics and mortality of cancer patients undergoing pericardiocentesis in the United States between 2004 and 2017.

Andrija Matetic, Bonnie Ky, Eric H Yang, Phyo K Myint, Muhammad Rashid, Shelley Zieroth, Timir K Paul, Ayman Elbadawi, Mamas A Mamas

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 4 countries.

Andrija MateticDepartment of Cardiology, University Hospital of Split, Split, Croatia.ORCID 0000-0001-9272-6906
Bonnie KyCardiovascular Division, Department of Medicine, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Eric H YangUCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California, Los Angeles, California, USA.
Phyo K MyintAberdeen Cardiovascular & Diabetes Centre, University of Aberdeen, Aberdeen, UK.
Muhammad RashidKeele Cardiovascular Research Group, Keele University, Keele, UK.
Shelley ZierothSection of Cardiology, Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Timir K PaulDepartment of Cardiovascular Sciences, University of Tennessee at Nashville, Nashville, Tennessee, USA.
Ayman ElbadawiDivision of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Mamas A MamasKeele Cardiovascular Research Group, Keele University, Keele, UK.
Keele University · GBThe University of Texas Southwestern Medical Center · USUniversity of Aberdeen · GBUniversity of California, Los Angeles · USUniversity of Manitoba · CAUniversity of Pennsylvania · USUniversity of Tennessee at Martin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPericardiocentesis is undertaken in patients with cancer for diagnostic and therapeutic purposes. However, there are limited data on the frequency, characteristics and mortality of patients with different cancers undergoing pericardiocentesis.

methodsAll hospitalisations of adult cancer patients (≥18 years) in the US National Inpatient Sample between January 2004 and December 2017 were included. The cohort was stratified by discharge code of pericardiocentesis and cancer, using the International Classification of Diseases. The prevalence of pericardiocentesis, patient characteristics, cancer types and in-hospital all-cause mortality were analysed between cancer patients undergoing pericardiocentesis versus not.

resultsA total of 19,773,597 weighted cancer discharges were analysed, out of which 18,847 (0.1%) underwent pericardiocentesis. The most common cancer types amongst the patients receiving pericardiocentesis were lung (51.3%), haematological (15.9%), breast (5.4%), mediastinum/heart (3.2%), gastroesophageal (2.2%) and female genital cancer (1.8%), whilst 'other' cancer types were present in 20.2% patients. Patients undergoing pericardiocentesis had significantly higher mortality (15.6% vs. 4.2%, p < 0.001) compared to their counterparts. The presence of metastatic disease (aOR 2.67 95% CI 1.79-3.97), weight loss (aOR 1.48 95% CI 1.33-1.65) and coagulopathy (aOR 3.22 95% CI 1.63-6.37) were each independently associated with higher mortality in patients who underwent pericardiocentesis.

conclusionPericardiocentesis is an infrequent procedure in cancer patients and is most commonly performed in patients with lung, haematological and breast cancer. Cancer patients undergoing pericardiocentesis have increased mortality, irrespective of the underlying cancer type.

Indexed as

Breast NeoplasmsPericardiocentesisAdultFemaleHospital MortalityHumansInpatientsPrevalenceRetrospective StudiesUnited Statescancercharacteristicsoutcomespericardiocentesisprevalence

Identifiers

PMID36266946
PMCPMC10028040
OpenAlexW4306965990

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read104
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.